Isolated pelvic hyperthermochemotherapeutic perfusion--an experimental study on isolating efficacy.
Hyperthermochemotherapeutic perfusion model through isolated pelvic vessels was developed to evaluate the leakage of hyperthermia and drugs (such as adriamycin) from the isolated pelvic circulation to systemic circulation and its associated side/toxic effects. The isolated pelvic circulation was perfused through a femoral artery catheter with hyperthermic (48 degrees C to 55 degrees C) adriamycin solution (50 micrograms/ml) for 30 min. The efflux was drained through a femoral vein catheter. And the pelvic temperature was kept at the level of 43 +/- 0.5 degrees C. The temperature of pelvic circulation was kept at 4 degrees C to 5 degrees C greater than the systemic/core temperature. The adriamycin concentration of pelvic efflux was 12 to 46 folds of that of systemic serum. The difference between them was very significant (P < 0.001). As the perfusion pressure was increased, which kept lower than the mean systemic artery pressure, the leakage of the adriamycin from the isolated pelvic circulation to systemic circulation was increased, but there was no significant difference between them (P > 0.05). During isolated perfusion, the systemic blood dynamics remained stable and there were no organic injuries on the important organs. It was suggested that the isolating efficacy of the modality of isolated pelvic hyperthermochemotherapeutic perfusion through vessels was rather high. The hyperthermia and drugs could be effectively limited in the isolated pelvic region with minor side effects on the systemic circulation and important organs.
Zhang
J
J
Department of General Surgery, Xiehe Hospital, Tongji Medical University, Wuhan 430022.
Zheng
Q
Q
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006979:Hyperthermia, Induced; D008297:Male; D009374:Neoplasms, Experimental / Q000628:therapy; D010388:Pelvis / Q000098:blood supply; D011817:Rabbits
D000970:Antineoplastic Agents; D004317:Doxorubicin